Inflammation-mediated carcinogenesis develops in the context of chronic inflammation and is a significant cause of cancer within the digestive system.In the chronic inflammation microenvironment,the metabolic activity...Inflammation-mediated carcinogenesis develops in the context of chronic inflammation and is a significant cause of cancer within the digestive system.In the chronic inflammation microenvironment,the metabolic activity of tissue cells undergoes extensive changes,which interfere with the normal function of immune cells.Dysregulation of cell metabolism and immune function has been identified as a key factor contributing to inflammation-mediated carcinogenesis within the major digestive organs,such as the stomach,liver,and colorectum.This metabolic-immune imbalance also corresponds to traditional Chinese medicine(TCM)theories of“yin-yang disharmony”and“disharmony between Ying-nutrients and Wei-defense.”The metabolic-immune imbalance has also been regarded as the key factor supporting“treatment of different diseases with the same method”,in which the same approach is adopted in the treatment of different conditions.In the TCM treatment process,it is necessary to first identify TCM patterns and then apply the corresponding TCM to correct the dysregulated metabolic and immune function,thereby blocking the progression from inflammation to malignancy.Our study findings deepen the TCM understanding of metabolic-immune dysregulation and the relationship between metabolic-immune dysregulation,pattern identification,and treatment method.They also provide new insights for the treatment of inflammation-mediated carcinogenesis in major digestive organs and help us further explore the scientific connotation of the TCM strategy of“treating different diseases with the same method”.展开更多
Objective:To explore the common mechanism of Huanglian Jiedu Decoction in treating coronary heart disease and type 2 diabetes by network pharmacology.Methods:All chemical components and targets of the four drugs in Hu...Objective:To explore the common mechanism of Huanglian Jiedu Decoction in treating coronary heart disease and type 2 diabetes by network pharmacology.Methods:All chemical components and targets of the four drugs in Huanglian Jiedu Decoction were retrieved through TCMSP,and the genes were standardized through Uniprot database.Acquire disease targets related to coronary heart disease and diabetes in OMIM and GeneCards databases.The network diagram of"drug-component-target-disease"is constructed by using the software of cytopscape 3.7.2,the PPI network diagram of protein interaction is constructed by using STRING database,and the network diagram of"drug-disease"core target is constructed by using the software of cytopscape 3.7.2.DAVID's online database platform was used to analyze GO biological process and KEGG pathway enrichment of common targets of Huanglian Jiedu Decoction in treating coronary heart disease and type 2 diabetes.Results:103 active ingredients of Huanglian Jiedu Decoction were retrieved,including 140 acting targets,5342 coronary heart disease targets,114 diabetes targets,and 14 common intersection targets of drugs and diseases,involving AR,PPARG,TNF,IL6,CCL2,VEGFA,PON1,etc.The GO biological process analysis results in 98 biological processes,10 cell components and 10 molecular functions.Among them are positive regulation of gene expression,positive regulation of nitric oxide biosynthesis process,Extracellular space,cytokine activity,steroid hormone receptor activity and other biological processes;The enrichment analysis of KEGG pathway yielded 20 signal pathways(P≤0.05).It mainly involves Malaria,cancer in cancer,HIF-1 signaling pathway,TNF signaling pathway,NOD-like receptor signaling pathway,PI3K-Akt signaling pathway,etc.Conclusion:Huanglian Jiedu Decoction"treats different diseases at the same time"coronary heart disease and type 2 diabetes have the characteristics of multiple components,multiple targets and multiple pathways,which provide theoretical basis for Huanglian Jiedu Decoction to treat coronary heart disease and type 2 diabetes in clinic,but the key targets and pathways of Huanglian Jiedu Decoction to treat diseases still need further experimental verification.展开更多
目的基于多软件协同数据挖掘技术,从“异病同治”角度探讨近5年针灸治疗神经性皮炎及带状疱疹后遗神经痛的选穴规律。方法交叉检索中英文数据库(中国知网、万方数据知识服务平台、维普网、Medline、Embase、Web of Science),2018年1月1...目的基于多软件协同数据挖掘技术,从“异病同治”角度探讨近5年针灸治疗神经性皮炎及带状疱疹后遗神经痛的选穴规律。方法交叉检索中英文数据库(中国知网、万方数据知识服务平台、维普网、Medline、Embase、Web of Science),2018年1月1日—2022年12月31日发表的关于针灸治疗神经性皮炎及带状疱疹后遗神经痛的期刊文献。依据纳排标准筛选文献,用Zotero 6.0.26管理原始文献,用Microsoft Excel 16.54建立针灸处方数据库并对录入的针灸处方进行数据清洗、统计分析及可视化处理。结果本研究纳入神经性皮炎针灸处方31个、带状疱疹后遗神经痛针灸处方34个。腧穴使用频次均以阿是穴为首,除阿是穴外其他腧穴集中分布于足太阳膀胱经,且五输穴在特定穴中占比最高。神经性皮炎及带状疱疹后遗神经痛针灸处方共有的核心腧穴为“阿是穴-血海-三阴交”,共有核心穴对为“血海-阿是穴”。对高频腧穴进行聚类分析,分别聚为3类,其中阿是穴在2种疾病针灸处方中均单独成类。结论针灸治疗神经性皮炎和带状疱疹后遗神经痛所选腧穴具有高度一致性,与“异病同治”理论相符,但在腧穴配伍上又存在一定差异,说明2种疾病在病机上各有侧重,临床应结合实际情况辨证治疗,加减选穴。展开更多
[目的]运用网络药理学与分子对接技术探究桂枝茯苓丸“异病同治”治疗缺血性卒中、蛛网膜下腔出血、轻度认知障碍、失眠障碍、癫痫以及血管性头痛的作用机制。[方法]通过中药系统药理学数据库与分析平台(Traditional Chinese Medicine S...[目的]运用网络药理学与分子对接技术探究桂枝茯苓丸“异病同治”治疗缺血性卒中、蛛网膜下腔出血、轻度认知障碍、失眠障碍、癫痫以及血管性头痛的作用机制。[方法]通过中药系统药理学数据库与分析平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,TCMSP)、Swiss Target Prediction数据库以及PubChem平台预测桂枝茯苓丸组方药物的核心活性成分及对应靶点;检索DrugBank、疾病基因网络(Disease Gene Network,DisGeNET)、基因组注释数据平台(Genome Annotation Database Platform,GeneCards)及在线人类孟德尔遗传(Online Mendelian Inheritance in Man,OMIM)数据库获取疾病相关靶点,得到药物-疾病交集靶点;采用Cytoscape 3.9.1软件构建“药物-疾病-成分-靶点”网络和蛋白互作(protein-protein interaction,PPI)网络图,通过Metascape数据库对交集靶点进行核心靶点的基因本体(gene ontology,GO)功能和京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)通路富集分析。利用AutoDock Vina软件对核心成分和关键靶点进行分子对接验证。[结果]筛选去重后共获取桂枝茯苓丸核心活性成分155个,相关靶点672个,脑病靶点196个,药物-疾病交集靶点78个,其中桂枝茯苓丸“异病同治”脑病的5个核心活性成分为丹皮酚、槲皮素、芍药苷、肉桂醛、苦杏仁苷,PPI筛选得到5个关键靶点分别为白细胞介素-6(interleukin-6,IL6)、肿瘤坏死因子(tumor necrosis factor,TNF)、胰岛素(insulin,INS)、RAC-α丝氨酸/苏氨酸蛋白激酶(RAC-alpha serine/threonine-protein kinase,AKT1)、白细胞介素-1β(interleukin-1β,IL1B),KEGG富集分析显示主要通路分别为脂质与动脉粥样硬化、流体剪切力与动脉粥样硬化、癌症中的通路、糖尿病并发症中的高级糖基化终末产物-受体(advanced glycation end products-receptor of advanced glycation end products,AGEs-RAGE)信号通路、阿尔茨海默病、神经退行性变-多发性疾病中的通路。分子对接结果显示核心活性成分和关键靶点之间结合活性较好。[结论]本研究阐述了桂枝茯苓丸“异病同治”脑病多成分、多靶点、多通路的可能机制,为进一步了解桂枝茯苓丸的作用机制,探索新的临床应用和实验探究提供了一定的理论依据和参考。展开更多
基金supported by National Natural Science Foundation of China(92059102 and 81630080)the National Key Research and Development Plan of China(2018YFC1704106).
文摘Inflammation-mediated carcinogenesis develops in the context of chronic inflammation and is a significant cause of cancer within the digestive system.In the chronic inflammation microenvironment,the metabolic activity of tissue cells undergoes extensive changes,which interfere with the normal function of immune cells.Dysregulation of cell metabolism and immune function has been identified as a key factor contributing to inflammation-mediated carcinogenesis within the major digestive organs,such as the stomach,liver,and colorectum.This metabolic-immune imbalance also corresponds to traditional Chinese medicine(TCM)theories of“yin-yang disharmony”and“disharmony between Ying-nutrients and Wei-defense.”The metabolic-immune imbalance has also been regarded as the key factor supporting“treatment of different diseases with the same method”,in which the same approach is adopted in the treatment of different conditions.In the TCM treatment process,it is necessary to first identify TCM patterns and then apply the corresponding TCM to correct the dysregulated metabolic and immune function,thereby blocking the progression from inflammation to malignancy.Our study findings deepen the TCM understanding of metabolic-immune dysregulation and the relationship between metabolic-immune dysregulation,pattern identification,and treatment method.They also provide new insights for the treatment of inflammation-mediated carcinogenesis in major digestive organs and help us further explore the scientific connotation of the TCM strategy of“treating different diseases with the same method”.
基金National Major Specialized Science and Technology Project for New Drugs Development(No.2017ZX09301003)。
文摘Objective:To explore the common mechanism of Huanglian Jiedu Decoction in treating coronary heart disease and type 2 diabetes by network pharmacology.Methods:All chemical components and targets of the four drugs in Huanglian Jiedu Decoction were retrieved through TCMSP,and the genes were standardized through Uniprot database.Acquire disease targets related to coronary heart disease and diabetes in OMIM and GeneCards databases.The network diagram of"drug-component-target-disease"is constructed by using the software of cytopscape 3.7.2,the PPI network diagram of protein interaction is constructed by using STRING database,and the network diagram of"drug-disease"core target is constructed by using the software of cytopscape 3.7.2.DAVID's online database platform was used to analyze GO biological process and KEGG pathway enrichment of common targets of Huanglian Jiedu Decoction in treating coronary heart disease and type 2 diabetes.Results:103 active ingredients of Huanglian Jiedu Decoction were retrieved,including 140 acting targets,5342 coronary heart disease targets,114 diabetes targets,and 14 common intersection targets of drugs and diseases,involving AR,PPARG,TNF,IL6,CCL2,VEGFA,PON1,etc.The GO biological process analysis results in 98 biological processes,10 cell components and 10 molecular functions.Among them are positive regulation of gene expression,positive regulation of nitric oxide biosynthesis process,Extracellular space,cytokine activity,steroid hormone receptor activity and other biological processes;The enrichment analysis of KEGG pathway yielded 20 signal pathways(P≤0.05).It mainly involves Malaria,cancer in cancer,HIF-1 signaling pathway,TNF signaling pathway,NOD-like receptor signaling pathway,PI3K-Akt signaling pathway,etc.Conclusion:Huanglian Jiedu Decoction"treats different diseases at the same time"coronary heart disease and type 2 diabetes have the characteristics of multiple components,multiple targets and multiple pathways,which provide theoretical basis for Huanglian Jiedu Decoction to treat coronary heart disease and type 2 diabetes in clinic,but the key targets and pathways of Huanglian Jiedu Decoction to treat diseases still need further experimental verification.
文摘[目的]运用网络药理学与分子对接技术探究桂枝茯苓丸“异病同治”治疗缺血性卒中、蛛网膜下腔出血、轻度认知障碍、失眠障碍、癫痫以及血管性头痛的作用机制。[方法]通过中药系统药理学数据库与分析平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,TCMSP)、Swiss Target Prediction数据库以及PubChem平台预测桂枝茯苓丸组方药物的核心活性成分及对应靶点;检索DrugBank、疾病基因网络(Disease Gene Network,DisGeNET)、基因组注释数据平台(Genome Annotation Database Platform,GeneCards)及在线人类孟德尔遗传(Online Mendelian Inheritance in Man,OMIM)数据库获取疾病相关靶点,得到药物-疾病交集靶点;采用Cytoscape 3.9.1软件构建“药物-疾病-成分-靶点”网络和蛋白互作(protein-protein interaction,PPI)网络图,通过Metascape数据库对交集靶点进行核心靶点的基因本体(gene ontology,GO)功能和京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)通路富集分析。利用AutoDock Vina软件对核心成分和关键靶点进行分子对接验证。[结果]筛选去重后共获取桂枝茯苓丸核心活性成分155个,相关靶点672个,脑病靶点196个,药物-疾病交集靶点78个,其中桂枝茯苓丸“异病同治”脑病的5个核心活性成分为丹皮酚、槲皮素、芍药苷、肉桂醛、苦杏仁苷,PPI筛选得到5个关键靶点分别为白细胞介素-6(interleukin-6,IL6)、肿瘤坏死因子(tumor necrosis factor,TNF)、胰岛素(insulin,INS)、RAC-α丝氨酸/苏氨酸蛋白激酶(RAC-alpha serine/threonine-protein kinase,AKT1)、白细胞介素-1β(interleukin-1β,IL1B),KEGG富集分析显示主要通路分别为脂质与动脉粥样硬化、流体剪切力与动脉粥样硬化、癌症中的通路、糖尿病并发症中的高级糖基化终末产物-受体(advanced glycation end products-receptor of advanced glycation end products,AGEs-RAGE)信号通路、阿尔茨海默病、神经退行性变-多发性疾病中的通路。分子对接结果显示核心活性成分和关键靶点之间结合活性较好。[结论]本研究阐述了桂枝茯苓丸“异病同治”脑病多成分、多靶点、多通路的可能机制,为进一步了解桂枝茯苓丸的作用机制,探索新的临床应用和实验探究提供了一定的理论依据和参考。
